Find trials
Consejos para buscar

Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes

Overview

Información sobre este estudio

This purpose of this study is to determine if activation of a person's immune system in the small intestine could be a contributing cause of Type 1 Diabetes.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

For the Diabetes Cohort:

Inclusion Criteria:

  • Initial diagnosis for Type 1 Diabetes Mellitus (DM) must be within the past 6 months.
  • Clinical criteria used to diagnose T1D include at least some of the following : Diabetic ketoacidosis, Polyuria, Polydipsia, weight loss, need for insulin from diagnosis, BMI less than 30, C-peptide < 200 pmol/L or 0.6 ng/ml, Presence of Type 1 Diabetes Associated Antibodies

Exclusion Criteria:

  • Subjects on antibiotics, proton pump inhibitors, aspirin, non-steroidal anti-inflammatory drugs, alcohol intake within 48 hours, a bowel preparation with 4 weeks of the studies, and smokers
  • Subjects will be asked not to take any probiotics in the week before testing.
  • Any known intestinal inflammation such as Gastroesophageal Reflux Disease (GERD), eosinophilic esophagitis, and inflammatory bowel disease.
  • Prior gastrointestinal surgery (other than appendectomy)
  • Ongoing use of antiplatelet agents or anticoagulants.
  • Diabetic patients should not have a prior history of or family history of Celiac Disease (CD).
  • Subjects unable to provide informed consent
  • The presence of any medical or psychological condition that could interfere with the safe performance of the upper endoscopy.
  • Females cannot be pregnant

For the Healthy Control Cohort:

Inclusion Criteria:

  •  Healthy subjects

Exclusion Criteria:

  • Controls should not have a family history of DM or CD
  • Subjects on antibiotics, proton pump inhibitors, aspirin, non-steroidal anti-inflammatory drugs, alcohol intake within 48 hours, a bowel preparation with 4 weeks of the studies, and smokers
  • Subjects will be asked not to take any probiotics in the week before testing.
  • Any known intestinal inflammation such as Gastroesophageal Reflux Disease (GERD), eosinophilic esophagitis, and inflammatory bowel disease.
  • Prior gastrointestinal surgery (other than appendectomy)
  • Ongoing use of antiplatelet agents or anticoagulants.
  • Subjects unable to provide informed consent
  • The presence of any medical or psychological condition that could interfere with the safe performance of the upper endoscopy.
  • Females cannot be pregnant

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Joseph Murray, M.D.

Cerrado para la inscripción

Contact information:

Carol Van Dyke CCRP

(507) 266-7842

VanDyke.Carol@mayo.edu

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20113372

Mayo Clinic Footer